Macquarie Group
PCRX icon

Macquarie Group’s Pacira BioSciences PCRX Stock Holding History

Macquarie Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-469
Closed -$11.7K – 1739
2025
Q1 		$11.7K Buy
+469
New +$11.2K ﹤0.01% 1633
2024
Q3 		– Sell
-1,567,013
Closed -$44.8M – 1845
2024
Q2 		$44.8M Buy
1,567,013
+5,974
+0.4% +$170K 0.05% 447
2024
Q1 		$45.6M Buy
1,561,039
+176,876
+13% +$5.43M 0.05% 457
2023
Q4 		$46.7M Sell
1,384,163
-277,750
-17% -$8.13M 0.05% 443
2023
Q3 		$51M Buy
1,661,913
+935,255
+129% +$33.7M 0.06% 404
2023
Q2 		$29.1M Sell
726,658
-508,840
-41% -$21M 0.03% 572
2023
Q1 		$50.4M Sell
1,235,498
-801,551
-39% -$31.9M 0.06% 421
2022
Q4 		$78.7M Sell
2,037,049
-896,749
-31% -$43.6M 0.09% 298
2022
Q3 		$156M Sell
2,933,798
-630,109
-18% -$35M 0.19% 125
2022
Q2 		$208M Sell
3,563,907
-497,905
-12% -$32.6M 0.23% 89
2022
Q1 		$310K Buy
4,061,812
+286,509
+8% +$19.1M 0.24% 75
2021
Q4 		$227M Buy
3,775,303
+89,549
+2% +$4.94M 0.19% 122
2021
Q3 		$206M Sell
3,685,754
-29,510
-0.8% -$1.7M 0.18% 133
2021
Q2 		$225M Buy
3,715,264
+423,133
+13% +$26.8M 0.19% 114
2021
Q1 		$231M Buy
3,292,131
+538,103
+20% +$38.4M 0.33% 55
2020
Q4 		$165M Buy
2,754,028
+307,942
+13% +$18M 0.24% 87
2020
Q3 		$147M Buy
2,446,086
+420,314
+21% +$24.4M 0.25% 74
2020
Q2 		$106M Buy
2,025,772
+318,464
+19% +$13.3M 0.18% 107
2020
Q1 		$57.2M Sell
1,707,308
-364,866
-18% -$15.2M 0.12% 170
2019
Q4 		$93.9M Buy
2,072,174
+276,319
+15% +$11.7M 0.13% 130
2019
Q3 		$68.4M Sell
1,795,855
-114,439
-6% -$4.57M 0.11% 181
2019
Q2 		$83.1M Buy
1,910,294
+104,428
+6% +$4.43M 0.14% 137
2019
Q1 		$68.7M Sell
1,805,866
-330,466
-15% -$12.9M 0.12% 164
2018
Q4 		$91.9M Sell
2,136,332
-317,556
-13% -$14.8M 0.18% 98
2018
Q3 		$121M Buy
2,453,888
+132,763
+6% +$5.74M 0.2% 89
2018
Q2 		$74.4M Buy
2,321,125
+768,011
+49% +$26.5M 0.13% 147
2018
Q1 		$48.4M Buy
1,553,114
+286,700
+23% +$10.2M 0.09% 226
2017
Q4 		$57.8M Buy
1,266,414
+111,869
+10% +$4.43M 0.1% 185
2017
Q3 		$43.4M Buy
1,154,545
+63,015
+6% +$2.54M 0.08% 240
2017
Q2 		$52.1M Buy
1,091,530
+16,760
+2% +$778K 0.1% 179
2017
Q1 		$49M Buy
1,074,770
+67,321
+7% +$2.91M 0.09% 193
2016
Q4 		$32.5M Sell
1,007,449
-140,130
-12% -$4.68M 0.06% 290
2016
Q3 		$39.3M Buy
1,147,579
+1,016,103
+773% +$39.8M 0.08% 237
2016
Q2 		$4.43M Buy
131,476
+52,086
+66% +$2.56M ﹤0.01% 909
2016
Q1 		$4.21M Buy
+79,390
New +$4.64M 0.01% 750
2014
Q3 		– Sell
-21,329
Closed -$1.96M – 1583
2014
Q2 		$1.96M Buy
21,329
+4,989
+31% +$380K ﹤0.01% 1043
2014
Q1 		$1.14M Sell
16,340
-8,641
-35% -$588K ﹤0.01% 1139
2013
Q4 		$1.44M Buy
24,981
+2,910
+13% +$153K ﹤0.01% 1082
2013
Q3 		$1.06M Buy
+22,071
New +$804K ﹤0.01% 1153

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Macquarie Group's PCRX Position: Q2 2025 in Review

Macquarie Group sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 469 shares — an estimated $11.7K sold.

Macquarie Group first reported a position in PCRX in Q3 2013 and held it in 39 quarters. The position peaked at $231M in Q1 2021. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

  • Macquarie Group reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
  • Macquarie Group sold 469 Pacira BioSciences shares in Q2 2025, an estimated $11.7K.
  • Macquarie Group first reported a position in Pacira BioSciences in Q3 2013 and held it in 39 quarters.
  • Macquarie Group's Pacira BioSciences position peaked at $231M in Q1 2021.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Macquarie Group's 13F filing for Q2 2025, filed 14 Aug 2025.